| Stereochemistry | RACEMIC |
| Molecular Formula | C22H26FN3O2S |
| Molecular Weight | 415.524 |
| Optical Activity | ( + / - ) |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CN(C1CCN(CC(O)COC2=CC=C(F)C=C2)CC1)C3=NC4=CC=CC=C4S3
InChI
InChIKey=IGMKTIJBFUMVIN-UHFFFAOYSA-N
InChI=1S/C22H26FN3O2S/c1-25(22-24-20-4-2-3-5-21(20)29-22)17-10-12-26(13-11-17)14-18(27)15-28-19-8-6-16(23)7-9-19/h2-9,17-18,27H,10-15H2,1H3
| Molecular Formula | C22H26FN3O2S |
| Molecular Weight | 415.524 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | RACEMIC |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Optical Activity | ( + / - ) |
Sabeluzole (previously known as R 58 735) was developed for the treatment of Alzheimer's disease. It reached phase II clinical trials in Canada and Belgium before its development was discontinued. This drug possibly acts as N-methyl-D-aspartate (NMDA) receptor antagonist. In addition, the effect of sabeluzole on sleep, breathing and daytime symptoms was investigated in 13 patients with obstructive sleep apnea. Besides, no beneficial effect of sabeluzole was shown on peripheral nerve function in patients at an early stage of diabetic polyneuropathy.
Approval Year
PubMed
Patents
|
|
ENANTIOMER -> RACEMATE | |||
|
|
ENANTIOMER -> RACEMATE |
Showing 1 to 2 of 2 entries
